ABCL
AbCellera Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$12.28
+0.82%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$12.38
From 52W high−17.14%
Volume2.67M
Market cap$3.98B
P/E (TTM)—
P/S (TTM)60.1x
Div yield—
Key dataNov 4, 2026
Open
$12.38
From 52W high
−17.14%
Volume
2.67M
Market cap
$3.98B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−21.2x
P/E (TTM)
—
RSI (14)
46.7
MomentumView details →
1D Return
+0.82%
YTD Return
+244.44%
SummaryUpdated Jun 1, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company founded in 2012 and headquartered in Vancouver, Canada. The company went public in December 2020 during the height of the COVID-19 pandemic, largely driven by its successful collaboration with Eli Lilly to develop bebtelovimab, a COVID-19 antibody treatment. AbCellera has since transitioned from primarily being a platform and partnership company to becoming a clinical-stage biotechnology company focused on developing its own pipeline of antibody therapeutics while maintaining selective strategic partnerships.
Similar companies
Latest newsMore news →
AbCellera announced it will report its third quarter 2026 financial results on November 9, 2026.34d agoAbCellera Biologics shares surged 121% over three months amid positive ABCL635 data, major partnerships and a stronger financial position.43d agoAbCellera announced the presentation of Phase 2 data for ABCL635 at the IMS World Congress on Menopause 2026.49d ago